• 1
    Watkins K, Connell CM. Measurement of health-related QOL in diabetes mellitus. Pharmacoeconomics 2004; 22: 11091126.
  • 2
    Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. J Am Med Assoc 1998; 280: 14901496.
  • 3
    Redekop WK, Koopmanschap MA, Stolk RP, Rutten GE, Wolffenbuttel BH, Niessen LW. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care 2002; 25: 458463.
  • 4
    Coffey JT, Brandle M, Zhou H, Marriott D, Burke R, Tabaei BP et al. Valuing health-related quality of life in diabetes. Diabetes Care 2002; 25: 22382243.
  • 5
    Davis RE, Morrissey M, Peters JR, Wittrup-Jensen K, Kennedy-Martin T, Currie CJ. Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Opin 2005; 21: 14771483.
  • 6
    UK Prospective Diabetes Study Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 1999; 22: 11251136.
  • 7
    Best JH, Boye KS, Rubin RR, Cao D, Kim TH, Peyrot M. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabet Med 2009; 26: 722728.
  • 8
    Gallwitz B. Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus. Treat Endocrinol 2005; 4: 361370.
  • 9
    Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2008; 31: 111.
  • 10
    Arulmozhi DK, Portha B. GLP-1 based therapy for type 2 diabetes. Eur J Pharm Sci 2006; 28: 96108.
  • 11
    Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges JP et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007; 30: 16081610.
  • 12
    Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473481.
  • 13
    Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32: 8490.
  • 14
    Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193203.
  • 15
    Bode B, Hale PM, Hammer M, Testa MA, Garber AJ. Patient-reported outcomes in subjects with type 2 diabetes treated with monotherapy regimens of once-daily human GLP-1 analogue liraglutide or glimepiride. 44th Annual Meeting of the European Association for the Study of Diabetes, Rome, Italy, 7–11 September 2008: P894.
  • 16
    Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 3947.
  • 17
    Bradley C. Diabetes Treatment Satisfaction Questionnaire. In: BradleyC, ed. Handbook of Psychology and Diabetes. Chur, Switzerland: Harwood Academic Publishers 1994: 111132.
  • 18
    Bradley C. Diabetes treatment satisfaction questionnaire. Change version for use alongside status version provides appropriate solution where ceiling effects occur. Diabetes Care 1999; 22: 530532.
  • 19
    Green J, Feinglos M. Update on type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigm. Int J Clin Pract Suppl 2007; 154: 311.
  • 20
    Sundaram M, Smith MJ, Revicki DA, Elswick B, Miller LA. Rasch analysis informed the development of a classification system for a diabetes-specific preference-based measure of health. J Clin Epidemiol 2009; 62: 845856.
  • 21
    Secnik Boye K, Matza LS, Oglesby A, Malley K, Kim S, Hayes RP et al. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health Qual Life Outcomes 2006; 4: 80.
  • 22
    Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: 12401250.
  • 23
    Bradley C. Feedback on the FDA’s February 2006 draft guidance on patient-reported outcome (PRO) measures from a developer of PRO measures. Health Qual Life Outcomes 2006; 4: 78.
  • 24
    Lewis KS, Bradley C, Knight G, Boulton AJ, Ward JD. A measure of treatment satisfaction designed specifically for people with insulin-dependent diabetes. Diabet Med 1988; 5: 235242.
  • 25
    Witthaus E, Stewart J, Bradley C. Improved psychological outcomes after initiation of insulin treatment in patients with type II diabetes. Diabetologia 2000; 43: A205.
  • 26
    DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. Br Med J 2002; 325: 746.
  • 27
    Witthaus E, Stewart J, Bradley C. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes. Diabet Med 2001; 18: 619625.
  • 28
    Petterson T, Lee P, Hollis S, Young B, Newton P, Dornan T. Well-being and treatment satisfaction in older people with diabetes. Diabetes Care 1998; 21: 930935.